Trial Watch: Toll-like receptor agonists in oncological indications
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Toll-like receptors (TLRs) are an evolutionarily conserved group of enzymatically inactive, single membrane-spanning proteins that recognize a wide panel of exogenous and endogenous danger signals. Besides constituting a crucial component of the innate immune response to bacterial and viral pathogens, TLRs appear to play a major role in anticancer immunosurveillance. In line with this notion, several natural and synthetic TLR ligands have been intensively investigated for their ability to boost tumor-targeting immune responses elicited by a variety of immunotherapeutic and chemotherapeutic interventions. Three of these agents are currently approved by the US Food and Drug Administration (FDA) or equivalent regulatory agencies for use in cancer patients: the so-called bacillus Calmette-Guérin, monophosphoryl lipid A, and imiquimod. However, the number of clinical trials testing the therapeutic potential of both FDA-approved and experimental TLR agonists in cancer patients is stably decreasing, suggesting that drug developers and oncologists are refocusing their interest on alternative immunostimulatory agents. Here, we summarize recent findings on the use of TLR agonists in cancer patients and discuss how the clinical evaluation of FDA-approved and experimental TLR ligands has evolved since the publication of our first Trial Watch dealing with this topic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
The Danger Model: A Renewed Sense of Self
Matzinger, P. (2002) · Science · doi:10.1126/science.1071059 · Cited by 4,205
Circulating mitochondrial DAMPs cause inflammatory responses to injury
Zhang, Q., Raoof, M., Chen, Y., Sumi, Y., Sursal, T., Junger, W., Brohi, K., Itagaki, K., & Hauser, C. J. (2010) · Nature · doi:10.1038/nature08780 · Cited by 3,812 · cited 1×
“Reflecting their ligand-binding profile, TLRs are not only crucial for the initiation of an innate immune response against bacterial and viral pathogens,(7,8) but also participate in the organismal reaction to inflammatory conditions that usually do not involve a microbial component, including a wide array of neoplasm…”
Toll-like receptors and their crosstalk with other innate receptors in infection and immunity
Kawai, T., & Akira, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.05.006 · Cited by 3,658 · cited 2×
“At present, 13 distinct TLRs have been identified in mice (Tlr1-Tlr13), 10 of which are also encoded by the human genome (TLR1-TLR10).(7,8) Conversely, TLR11 is a pseudogene and human cells are devoid of Tlr12 and Tlr13 homologs.”
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303 · cited 3×
“At least in part, this stems from the key role that some TLRs play in the perception of cell death as immunogenic.(79,80) Indeed, cancer cells subjected to specific therapeutic regimens, including irradiation, some forms of photodynamic therapy as well as doxorubicin-, mitoxantrone-, and oxaliplatin-based chemotherapy…”
Self-citationImmunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Sterile inflammation: sensing and reacting to damage
Chen, G. Y., & Nuñez, G. (2010) · Nature Reviews Immunology · doi:10.1038/nri2873 · Cited by 3,051 · cited 1×
“, endogenous molecules that are released by stressed, dying or dead cells as a signal of danger.(29-34) This is for instance the case of TLR2 and TLR4,(35-40) both of which are expressed on the cell surface (similar to other TLRs that recognize proteo-lipidic components),(8,41) as well as of TLR9,(42,43) which is main…”
The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling
O'Neill, L. A. J., & Bowie, A. G. (2007) · Nature Reviews Immunology · doi:10.1038/nri2079 · Cited by 2,667 · cited 1×
“Moreover, MYD88 and TIRAP have been shown to actively inhibit TLR3 signaling,(51-53) lending further support to the notion that the functional profile of TLR3 is rather dissimilar from that of other members of the TLR family.(8,41,54-56) Reflecting their ligand-binding profile, TLRs are not only crucial for the initia…”
Paavonen, J., Naud, P., Salmerón, J., Wheeler, C., Chow, S.-N., Apter, D., Kitchener, H., Castellsague, X., Teixeira, J., Skinner, Sr., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61248-4 · Cited by 1,655
Novel Signal Transduction Pathway Utilized by Extracellular HSP70
Asea, A., Rehli, M., Kabingu, E., Boch, J. A., Baré, O., Auron, P. E., Stevenson, M. A., & Calderwood, S. K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200497200 · Cited by 1,510
Vogl, T., Tenbrock, K., Ludwig, S., Leukert, N., Ehrhardt, C., van Zoelen, M. A. D., Nacken, W., Foell, D., van der Poll, T., Sorg, C., et al. (2007) · Nature Medicine · doi:10.1038/nm1638 · Cited by 1,418
Decoding cell death signals in liver inflammation
Brenner, C., Galluzzi, L., Kepp, O., & Kroemer, G. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.03.033 · Cited by 1,022 · cited 1×
“, endogenous molecules that are released by stressed, dying or dead cells as a signal of danger.(29-34) This is for instance the case of TLR2 and TLR4,(35-40) both of which are expressed on the cell surface (similar to other TLRs that recognize proteo-lipidic components),(8,41) as well as of TLR9,(42,43) which is main…”
Self-citationToll-like receptors and cancer
Rakoff-Nahoum, S., & Medzhitov, R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2541 · Cited by 925
CD36 is a sensor of diacylglycerides
Hoebe, K., Georgel, P., Rutschmann, S., Du, X., Mudd, S., Crozat, K., Sovath, S., Shamel, L., Hartung, T., Zähringer, U., et al. (2005) · Nature · doi:10.1038/nature03253 · Cited by 873 · cited 4×
“Besides constituting a crucial component of the innate immune response to bacterial and viral pathogens, tLrs appear to play a major role in anticancer immunosurveillance. in line with this notion, several natural and synthetic tLr ligands have been intensively investigated for their ability to boost tumor-targeting i…”
InfluentialMitochondria: master regulators of danger signalling
Galluzzi, L., Kepp, O., & Kroemer, G. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3479 · Cited by 733 · cited 1×
“, endogenous molecules that are released by stressed, dying or dead cells as a signal of danger.(29-34) This is for instance the case of TLR2 and TLR4,(35-40) both of which are expressed on the cell surface (similar to other TLRs that recognize proteo-lipidic components),(8,41) as well as of TLR9,(42,43) which is main…”
Self-citationStructural Basis of Toll-Like Receptor 3 Signaling with Double-Stranded RNA
Liu, L., Botos, I., Wang, Y., Leonard, J. N., Shiloach, J., Segal, D. M., & Davies, D. R. (2008) · Science · doi:10.1126/science.1155406 · Cited by 733
Anderson, K. V., Jürgens, G., & Nüsslein-Volhard, C. (1985) · Cell · doi:10.1016/0092-8674(85)90274-0 · Cited by 691
Inflammasomes in carcinogenesis and anticancer immune responses
Zitvogel, L., Kepp, O., Galluzzi, L., & Kroemer, G. (2012) · Nature Immunology · doi:10.1038/ni.2224 · Cited by 593 · cited 1×
“This said, Aldara (imiquimod 5% cream as commercialized by 3M Pharmaceuticals) has been shown to mediate TLR7-independent immunostimulatory effects, perhaps owing to the pro-inflammatory activity of isostearic acid.(97,98) Of note, picibanil – a lyophilized preparation of Streptococcus pyogenes that activates TLR2 and…”
Self-citationPredictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy
Ulloa-Montoya, F., Louahed, J., Dizier, B., Gruselle, O., Spiessens, B., Lehmann, F. F., Suciu, S., Kruit, W. H. J., Eggermont, A. M. M., Vansteenkiste, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.3762 · Cited by 436 · cited 2×
“The same signature, including several immunologically relevant genes (e.g., IFNγ-related genes, chemokinecoding genes), turned out to predict the likelihood of resected NSCLC patients to respond to full-length MAGEA3 plus AS15.”
Self-citationTLR13 Recognizes Bacterial 23 S rRNA Devoid of Erythromycin Resistance–Forming Modification
Oldenburg, M., Krüger, A., Ferstl, R., Kaufmann, A., Nees, G., Sigmund, A., Bathke, B., Lauterbach, H., Suter, M., Dreher, S., et al. (2012) · Science · doi:10.1126/science.1220363 · Cited by 405 · cited 4×
“Besides constituting a crucial component of the innate immune response to bacterial and viral pathogens, tLrs appear to play a major role in anticancer immunosurveillance. in line with this notion, several natural and synthetic tLr ligands have been intensively investigated for their ability to boost tumor-targeting i…”
InfluentialMarques, P. E., Amaral, S. S., Pires, D. A., Nogueira, L. L., Soriani, F. M., Lima, B. H. F., Lopes, G. A. O., Russo, R. C., Ávila, T. V., Melgaço, J. G., et al. (2012) · Hepatology · doi:10.1002/hep.25801 · Cited by 332
The IRF family of transcription factors: Inception, impact and implications in oncogenesis
Yanai, H., Negishi, H., & Taniguchi, T. (2012) · OncoImmunology · doi:10.4161/onci.22475 · Cited by 261
Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy
Dutoit, V., Herold-Mende, C., Hilf, N., Schoor, O., Beckhove, P., Bucher, J., Dorsch, K., Flohr, S., Fritsche, J., Lewandrowski, P., et al. (2012) · Brain · doi:10.1093/brain/aws042 · Cited by 201
Tai, L.-H., Zhang, J., Scott, K. J., de Souza, C. T., Alkayyal, A. A., Ananth, A. A., Sahi, S., Adair, R. A., Mahmoud, A. B., Sad, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0246 · Cited by 70
Cited by
Type I interferons in anticancer immunity
Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology · doi:10.1038/nri3845 · Cited by 1,305
Self-citationAntitumour actions of interferons: implications for cancer therapy
Parker, B. S., Rautela, J., & Hertzog, P. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.14 · Cited by 907
Consensus guidelines for the detection of immunogenic cell death
Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955691 · Cited by 832
Self-citationCombinatorial Strategies for the Induction of Immunogenic Cell Death
Bezu, L., Gomes-de-Silva, L. C., Dewitte, H., Breckpot, K., Fucikova, J., Spisek, R., Galluzzi, L., Kepp, O., & Kroemer, G. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00187 · Cited by 390
Self-citationTrial watch: IDO inhibitors in cancer therapy
Vacchelli, E., Aranda, F., Eggermont, A., Sautès-Fridman, C., Tartour, E., Kennedy, E. P., Platten, M., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.957994 · Cited by 326
Self-citation
Metadata
- Authors
- Aranda, F., Vacchelli, E., Obrist, F., Eggermont, A., Galon, J., Sautès-Fridman, C., Cremer, I., Henrik ter Meulen, J., Zitvogel, L., Kroemer, G., & Galluzzi, L.
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2014-06
- Volume
- 3
- Issue
- 6
- Pages
- e29179
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- OpenAlex
- W1966042340
- Cited by
- 81
- References
- 25
- FWCI
- 5.71
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.